Choksi Laboratories [CHOKSILA] vs Syngene [SYNGENE] Detailed Stock Comparison
Choksi Laboratories
BSE
Loading...
Syngene
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Choksi Laboratories wins in 5 metrics, Syngene wins in 13 metrics, with 0 ties. Syngene appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Choksi Laboratories | Syngene | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 101.93 | 52.80 | Syngene |
| Price-to-Book Ratio | 6.63 | 5.68 | Syngene |
| Debt-to-Equity Ratio | 123.52 | 12.23 | Syngene |
| PEG Ratio | N/A | 3.70 | N/A |
| EV/EBITDA | 16.17 | 25.99 | Choksi Laboratories |
| Profit Margin (TTM) | 3.52% | 13.61% | Syngene |
| Operating Margin (TTM) | 10.90% | 11.44% | Syngene |
| EBITDA Margin (TTM) | 10.90% | 11.44% | Syngene |
| Return on Equity | 6.45% | 10.50% | Syngene |
| Return on Assets (TTM) | 2.33% | 7.30% | Syngene |
| Free Cash Flow (TTM) | $40.91M | $3.98B | Syngene |
| Dividend Yield | N/A | 0.39% | N/A |
| 1-Year Return | 191.98% | -20.79% | Choksi Laboratories |
| Price-to-Sales Ratio (TTM) | 3.69 | 7.20 | Choksi Laboratories |
| Enterprise Value | $1.86B | $265.97B | Syngene |
| EV/Revenue Ratio | 4.39 | 7.14 | Choksi Laboratories |
| Gross Profit Margin (TTM) | 85.53% | 75.12% | Choksi Laboratories |
| Revenue per Share (TTM) | $61 | $93 | Syngene |
| Earnings per Share (Diluted) | $2.20 | $12.64 | Syngene |
| Beta (Stock Volatility) | 0.16 | 0.02 | Syngene |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Choksi Laboratories vs Syngene Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Choksi Laboratories | -0.34% | -1.92% | 15.70% | 98.51% | 73.94% | 144.17% |
| Syngene | -0.06% | 0.57% | -1.27% | 5.09% | -4.77% | -24.09% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Choksi Laboratories | 191.98% | 677.21% | 1,917.89% | 1,529.26% | 937.50% | 199.25% |
| Syngene | -20.79% | 11.22% | 36.75% | 308.02% | 317.07% | 317.07% |
Performance & Financial Health Analysis: Choksi Laboratories vs Syngene
| Metric | CHOKSILA | SYNGENE |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.56B | ₹268.17B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 14,560 | 679,784 |
| 90 Day Avg. Volume | 10,119 | 1,258,476 |
| Last Close | ₹219.95 | ₹667.40 |
| 52 Week Range | ₹56.16 - ₹236.70 | ₹599.55 - ₹960.60 |
| % from 52W High | -7.08% | -30.52% |
| All-Time High | ₹236.70 (Aug 20, 2025) | ₹960.60 (Dec 02, 2024) |
| % from All-Time High | -7.08% | -30.52% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.11% |
| Quarterly Earnings Growth | -0.09% | 0.15% |
| Financial Health | ||
| Profit Margin (TTM) | 0.04% | 0.14% |
| Operating Margin (TTM) | 0.11% | 0.11% |
| Return on Equity (TTM) | 0.06% | 0.11% |
| Debt to Equity (MRQ) | 123.52 | 12.23 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹33.82 | ₹117.59 |
| Cash per Share (MRQ) | ₹0.88 | ₹34.82 |
| Operating Cash Flow (TTM) | ₹51.38M | ₹5.00B |
| Levered Free Cash Flow (TTM) | ₹15.23M | ₹4.96B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.39% |
| Last 12-Month Dividend | N/A | ₹2.50 |
Valuation & Enterprise Metrics Analysis: Choksi Laboratories vs Syngene
| Metric | CHOKSILA | SYNGENE |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 101.93 | 52.80 |
| Forward P/E | N/A | 39.61 |
| PEG Ratio | N/A | 3.70 |
| Price to Sales (TTM) | 3.69 | 7.20 |
| Price to Book (MRQ) | 6.63 | 5.68 |
| Market Capitalization | ||
| Market Capitalization | ₹1.56B | ₹268.17B |
| Enterprise Value | ₹1.86B | ₹265.97B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.39 | 7.14 |
| Enterprise to EBITDA | 16.17 | 25.99 |
| Risk & Other Metrics | ||
| Beta | 0.16 | 0.02 |
| Book Value per Share (MRQ) | ₹33.82 | ₹117.59 |
Financial Statements Comparison: Choksi Laboratories vs Syngene
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CHOKSILA | SYNGENE |
|---|---|---|
| Revenue/Sales | ₹114.00M | ₹8.75B |
| Cost of Goods Sold | ₹16.49M | ₹2.18B |
| Gross Profit | ₹97.50M | ₹6.57B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹18.64M | ₹1.00B |
| EBITDA | ₹35.45M | ₹2.24B |
| Pre-Tax Income | ₹12.59M | ₹1.01B |
| Income Tax | ₹3.38M | ₹146.00M |
| Net Income (Profit) | ₹9.21M | ₹867.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CHOKSILA | SYNGENE |
|---|---|---|
| Cash & Equivalents | ₹6.12M | ₹3.67B |
| Total Current Assets | ₹163.21M | ₹22.87B |
| Total Current Liabilities | ₹238.75M | ₹13.96B |
| Long-Term Debt | ₹159.63M | ₹4.09B |
| Total Shareholders Equity | ₹236.05M | ₹47.27B |
| Retained Earnings | N/A | ₹38.82B |
| Property, Plant & Equipment | ₹471.35M | ₹27.42B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CHOKSILA | SYNGENE |
|---|---|---|
| Operating Cash Flow | N/A | ₹2.17B |
| Capital Expenditures | N/A | ₹-680.00M |
| Free Cash Flow | N/A | ₹1.27B |
| Debt Repayment | N/A | ₹0 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CHOKSILA | SYNGENE |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 14,560 | 679,784 |
| Average Daily Volume (90 Day) | 10,119 | 1,258,476 |
| Shares Outstanding | 6.97M | 401.37M |
| Float Shares | 3.37M | 175.53M |
| % Held by Insiders | 0.56% | 0.53% |
| % Held by Institutions | 0.00% | 0.32% |
Dividend Analysis & Yield Comparison: Choksi Laboratories vs Syngene
| Metric | CHOKSILA | SYNGENE |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹2.50 |
| Last 12-Month Dividend Yield | N/A | 0.39% |
| 3-Year Avg Annual Dividend | N/A | ₹1.25 |
| 3-Year Avg Dividend Yield | N/A | 0.14% |
| 3-Year Total Dividends | N/A | ₹3.75 |
| Ex-Dividend Date | N/A | Jun 27, 2025 |